Luis Jauregui, MD
Infectious Disease · Toledo, OHNPI 1578554242
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $257 of the $329 with a category attached, or 78.1%. It is spread thinly across 12 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations.
Across 14 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Products, LP$72
- Merck$38
- Baxter Healthcare$37
- Mylan Institutional Inc.$32
- AstraZeneca$24
- Pfizer$23
- plus $101 from 6 others
Across 50 payments — averaging $10,082 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$265K
- GSK$134K
- Hoffmann-la Roche Limited$60K
- Roche TCRC, Inc.$37K
- Pfizer$8K
What the payments were for
- Food & beverage$25778%
- Education$7222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Products, LP | 1 | $72 |
| Merck | 2 | $38 |
| Baxter Healthcare | 1 | $37 |
| Mylan Institutional Inc. | 2 | $32 |
| AstraZeneca | 1 | $24 |
| Pfizer | 1 | $23 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $22 |
| Smith+Nephew | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Sanofi | 1 | $15 |
| Insmed, Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $14 |
How this compares
$329 in reported general payments places this provider in the 55th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 32 | $1,138 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Toledo
- Nelson NicolasoraToledo$65K
- Tanyanyiwa ChinyadzaToledo$4K
- Steven BurdetteDayton$322K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Nicholas CongerWright Patterson Afb$76K
- Alan TaegeCleveland$76K
- Carlos MalvestuttoColumbus$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.